Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on the development of two orally available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company is focused on Phase II trials of AMP945 in patients with pancreatic cancer and idiopathic pulmonary fibrosis. The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH). It is also focused on a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).